

LIGAND

Biopharma's Technology
and Capital Partner

Third Quarter 2026 Financial Results

OCTOBER 29, 2026

Safe Harbor Statement and Disclaimers

- This presentation contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and its partners' judgment as of the date of this presentation. All statements, other than statements of historical fact, could be deemed to be forward-looking statements, including statements that express Ligand's or its partners' opinions, expectations, objectives, assumptions, plans or projections regarding future events or future results. In some instances, words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date hereof. These forward-looking statements include, without limitation: Ligand's ability to expand its portfolio with life sciences royalty opportunities; the timing of clinical and regulatory events of Ligand's partners and other commercialization and marketing efforts; the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners; the timing of product launches by Ligand or its partners; and guidance regarding projected 2026 financial results. Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand's business, including, without limitation: Ligand relies on collaborative partners for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue, royalty revenue and income for partners that had not reported product sales as of the date of this press release are based on estimates that may differ from actual results and if such results differ, they will be adjusted in future periods; Ligand may not receive expected revenue from Captisol material sales; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline or receive regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; Ligand may not achieve its financial guidance for 2026; Ligand faces competition in acquiring royalties and locating suitable royalties to acquire; Ligand may not be able to create future revenues and cash flows through the acquisition of royalties or by developing innovative therapeutics; products under development by Ligand or its partners may not receive regulatory approval; the total addressable market for our partners' products may be smaller than estimated; Ligand faces competition with respect to its technology platforms which may demonstrate greater market acceptance or superiority; Ligand is currently dependent on a single source sole supplier for Captisol and failures by such supplier may result in delays or inability to meet the Captisol demands of its partners; Ligand's partners may change their development focus and may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest; Ligand's collaboration partners may become insolvent; Ligand's and its partners' products may not be proved to be safe and efficacious and may not perform as expected and uncertainty regarding the commercial performance of such products; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated; cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and/or significant disruption to Ligand's business operations; Ligand's partners may terminate any of their agreements or the development or commercialization of any of its products; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, challenges, costs and charges associated with integrating acquisitions with Ligand's existing businesses; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs; restrictions under Ligand's credit agreement may limit its flexibility in operating its business and a default under the agreement could result in a foreclosure of the collateral securing such obligations; Ligand may not realize the anticipated benefits from investments such as convertible notes, including the 2031 convertible notes; Ligand may not successfully integrate the XOMA portfolio or realize the anticipated benefits of the XOMA acquisition; changes in general economic conditions, including as a result of war, conflict, epidemic diseases, the imposition and/or announcement of tariffs and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on Ligand; and other risks and uncertainties described in our public filings with the Securities and Exchange Commission (the "SEC"), available at www.sec.gov. Information regarding partnered products and programs comes from information publicly released by our partners. Our trademarks, trade names and service marks referenced herein include Ligand, Captisol, NITRICIL and ZELSUVMI. Each other trademark, trade name or service mark appearing in this presentation belongs to its owner.
- This presentation presents certain non-GAAP measures. A reconciliation between the non-GAAP adjusted financial numbers and corresponding GAAP figures is shown in our quarterly earnings press releases or the fiscal year annual report, available at <https://investor.ligand.com/news-and-events/press-releases/>.
- All forward looking statements are qualified in their entirety by this cautionary statement, and Ligand undertakes no obligation to revise or update this presentation to reflect events or circumstances or updated third party research numbers occurring after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934.

Strong Strategic Momentum in Third Quarter 2026

COMMERCIAL MOMENTUM

+51%

royalty revenue growth
YoY, to ~\$70M

**Filspari, Ohtuvayre
and Zelsuvmi** lead
growth; FSGS approval
expands Filspari
beyond IgAN

**Vabysmo, Ojemda
and Miplyffa** now
contribute

PORTFOLIO SCALE

16

key commercial royalty
assets

**Closed XOMA
acquisition** in July,
adding three key
commercial assets and
100+ pipeline
programs

DISCIPLINED DEPLOYMENT

180+

opportunities reviewed in
2026

Two new investments:
AvenCell (CAR-T) and
Ryjunea (pediatric
myopia)

**Scaled investment
team** expands our deal
capacity

FUTURE OUTLOOK

Up to 7

pivotal readouts
anticipated through 2027

**Five-year outlook
update** coming in
December

Foundation set for
long-term growth

Leadership Network Drives Deal Sourcing and Diligence

CORPORATE MANAGEMENT



Todd Davis
Chief Executive Officer



Tavo Espinoza
Chief Financial Officer



Andrew Reardon
Chief Legal Officer



INVESTMENTS



Paul Hadden
SVP, Investments & Business Development



Rich Baxter
SVP, Investment Operations



Lauren Hay
VP, Portfolio Strategy & Investments



Michael Vigilante
VP, Investments & Business Development



Pete Renehan, M.D.
VP, Investments & Business Development



Lee Brown
VP, Investments & Business Development



CLINICAL OPERATIONS & TECHNOLOGY



Karen Reeves, M.D.
SVP, Investments & Head of Clinical Strategy; General Manager, Captisol



Vince Antle, Ph.D.
SVP, Technical Operations & Quality



Keith Marschke, Ph.D.
SVP, Biology & Scientific Affairs



\$1B+ Invested Across 20+ Investments Since 2023

Royalty Monetization

Project Finance

Special Situations



\$30M

Oct '23



\$19M

Jan '24–Jan '25



\$40M

Jul '25



\$75M

May '24



\$8M

Nov '23–Jul '24



\$22M

Sep '23–Sep '26



\$73M

Sep '23–Nov '25



\$20M

Nov '23



\$11M

Sep '25



\$23M

Q3 '26



\$47M¹

Q3 '26



\$50M

Feb '25



\$100M

Jul '24




\$739M

Jul '26

Royalty Revenue On Track to Triple and EPS to Nearly Quadruple Since 2022


Royalty revenue

+34% CAGR, 2022–2026E



Adjusted EPS²

+41% CAGR, 2022–2026E



¹ 2026E shown at the midpoint of guidance (royalty revenue \$225M–\$250M, midpoint \$237.5M; adjusted EPS \$9.50–\$9.75, midpoint \$9.63). CAGR measured from 2022 to the 2026E midpoint

² Adjusted EPS is a non-gaap measure, see reconciliation to GAAP in our earnings release for the corresponding period



Financial Update

Tavo Espinoza

LIGAND

Third Quarter 2026 Highlights

ROYALTY REVENUE

\$70.3M¹

Third-quarter royalty revenue

+51% year-over-year

ADJUSTED EPS

\$2.67²

Adjusted diluted EPS

vs. **\$3.09** in Q3 2025
Q3 2025 included \$24.5M of one-time Zelsuvmi out-license income

CASH & INVESTMENTS

~\$450M

Cash, cash equivalents & short-term investments

vs. **\$734M** at year-end 2025
Decline reflects XOMA acquisition, partly offset by 2031 notes proceeds

DEPLOYABLE CAPITAL

~\$750M

Approximate deployable capital

Factoring in our equity holdings and credit facility

¹ Beginning Q3 2026, Ligand reports earlier in the quarterly cycle. Royalty revenue includes estimates for partners that had not reported as of the date of our presentation; differences are trued up in the following quarter. Income on financial royalty assets is driven by long-term forecasts of royalty cash flows rather than a single quarter of partner-reported sales; see our Form 10-K.

² Adjusted EPS represents a non-GAAP measure. See our Q3 26 earnings release for a reconciliation to the corresponding GAAP measure.

Q3 2026 Royalty Revenue Exceeds \$70 Million

ROYALTY REVENUE

+51%

year-over-year growth, to \$70.3M


LARGEST ROYALTY ASSET

\$16.8M¹

Filspari grew 85% from \$9.1M in Q3 2025 and overtook Kyprolis at \$10.5M

LEGACY VS. XOMA-ACQUIRED (\$M)

■ Legacy royalties ■ XOMA-acquired



Legacy royalties +25% YoY; XOMA-acquired assets added \$12.3M after the July 14 close

Q3 2026 PRODUCT MIX (\$M)²

Filspari **\$16.8M 24%**

Largest royalty asset, includes US and Ex-US

Ohtuvayre **\$7.0M 10%**

Includes royalty on net sales plus Ohtuvayre inventors royalty (FRA) income

Other **\$34.2M 49%**

Includes Kyprolis \$10.5M and Qarziba \$6.0M

XOMA **\$12.3M 17%**

Ojemda \$7.0M, Vabysmo \$3.6M, Miplyffa \$1.7M

NOTE: XOMA-acquired: Vabysmo, Miplyffa and Ojemda (XOMA acquisition closed July 14, 2026). Other includes Kyprolis, Qarziba, Rylaze, Capvaxive, Vaxneuvance, Zelsuvmi, teriparatide and other royalties. Amounts may not sum due to rounding

¹ Travers had not reported Q3 2026 Filspari sales as of the date of this presentation. The \$16.8M figure is an estimate based on sell-side consensus of ~\$170M in U.S. Filspari net product sales (FactSet consensus) plus Ligand's estimate of ~\$17M in Filspari net product sales for CSL Vifor Europe (approximately \$187 million in Q3 2026 net sales) applying a 9% royalty rate. The estimate may differ from actual results and if such results differ, they will be adjusted in future periods.

² Certain Q3 royalties are based on Ligand estimates, informed in part by sell-side consensus, and trued up to partner-reported results the following quarter

Third Quarter 2026 Financial Performance

\$ in millions, except for per share amounts (unaudited)	Three Months Ended September 30,	
	2026	2025
Revenues:		
Royalties	\$70.3	\$46.6
Captisol	7.9	10.7
Contract revenue and income ²	0.5	58.2
Total revenues	\$78.7	\$115.5
Less: Gain on sale of Pelthos business	-	(28.6)
Total core revenues¹	\$78.7	\$86.9
Operating costs and expenses:		
Cost of Captisol	2.7	3.8
Amortization of intangibles	10.2	8.1
R&D Expense	2.8	21.0
G&A Expense	72.6	28.4
Fair value adjustments to contingent liabilities	6.3	(0.5)
Fair value adjustments to partner program derivatives	-	(0.8)
Total Operating Expenses	94.5	60.1
Operating (Loss) Income	(15.8)	55.4
Non-Operating (Expense) Income, net	(28.3)	85.8
GAAP Net (Loss) Income	(28.5)	117.3
Non- GAAP Net Income¹	\$57.5	\$63.8
GAAP Diluted EPS	(\$1.43)	\$5.68
Non- GAAP Diluted EPS¹	\$2.67	\$3.09

- **Total core revenue¹ –9%** – Driven by \$24.5M Zelsuvmi out-license fee recorded in Q3 2025. Excluding the fee, **core revenue¹ grew +26%**
- **R&D** – Decrease driven by \$17.8M charge in Q3 2025 associated with the R&D funding arrangement with Orchestra BioMed
- **G&A** – Increase driven largely by one-time XOMA transaction costs, plus share-based compensation and expanded business development and investment team
- **2026 cash operating expenses²** – expected to approximate \$50M
- **Non-operating expense** – Variance driven by mark-to-market adjustments on equity investments
- **Adjusted EPS of \$2.67¹** – Excludes stock-based compensation, amortization of intangible and financial assets and certain transaction costs (see non-GAAP reconciliation in press release)

¹ Represents a non-GAAP financial measure. See non-GAAP reconciliation in the Q3 26 and Q3 25 earnings press releases.

² A reconciliation of forward-looking non-GAAP cash operating expenses to the most directly comparable GAAP measure is not available without unreasonable effort, as certain items cannot be reasonably predicted because of their high variability, complexity and low visibility.

NOTE: Amounts may not sum due to rounding

Share Dilution From 2030 & 2031 Convertible Transactions

At \$400, the call spread limits dilution to ~0.6M shares, or ~3% of current shares outstanding

\$460M, 0.75% convertible senior notes due 2030

\$700M, 0% convertible senior notes due 2031

- **Principal repaid in cash:** only value above the conversion price can be settled in shares
- **Bond hedge offsets** shares issued on conversion
- **Warrants raise the effective conversion price** to \$294.02 (2030) and \$524.34 (2031), 100% above the share price at pricing
- **GAAP shows higher dilution** because it excludes the bond hedge, which offsets those conversion shares

Ligand share price	Economic dilution ¹	GAAP basis ²
	Shares (M)	Diluted shares (M)
\$250	–	0.5
\$300	<0.1	0.9
\$350	0.4	1.5
\$400	0.6	2.2
\$450	0.8	2.7
\$500	1.0	3.1
\$550	1.2	3.5
\$600	1.5	4.0
\$650	1.7	4.4
\$700	1.9	4.7
\$750	2.1	5.0

¹ Illustrative only; shares from warrants after the offsetting bond hedge at various share prices which would be expected to add to the diluted share count for future adjusted EPS calculations.

² If-converted method (ASU 2020-06); excludes the bond hedge as anti-dilutive. Illustrative only; based on initial conversion rates and warrant strikes and ~22M shares outstanding; excludes conversion rate adjustments. Not a forecast of share price.

2026 Financial Guidance

Raising Adjusted EPS Guidance and Reaffirming Full-Year Revenue Guidance

Royalty Revenue

\$225–250M

Includes: Ojemda, Vabysmo and Miplyffa

Adjusted EPS¹

\$9.50–9.75

(Previously \$9.00–9.50)

Total Revenue

\$270–310M

Non-Royalty Revenue

Captisol: \$35–40M

Contract: \$10–20M

5-Year Outlook To Be Updated In December

Positive developments which are expected to drive an increase to the long-term outlook include:



Acquisition of XOMA is immediately accretive and is expected to drive significant growth



First FDA approved treatment in FSGS in April 2026, creating a significant commercial opportunity to expand beyond IgAN. Ligand earns a 9% royalty on net sales of Filspari



NDA acceptance and Priority Review of QTORIN rapamycin in MLM² with PDUFA date of February 28, 2027. Ligand will earn a tiered 8–9.8% royalty if approved

Ligand Expected Royalty Receipts¹





Portfolio Update

Lauren Hay

LIGAND

Key Commercial Programs

Ry Junea acquisition adds 16th Key Program to Commercial Portfolio

Marketer	Program	Indication	Royalty Rate
  	● Filspari	IgA Nephropathy; Focal Segmental Glomerulosclerosis	9%
  	Kyprolis	R/R Multiple Myeloma	Tiered 1.5% to 3%
 	● Qarziba	High-Risk Neuroblastoma	Tiered mid-teens
	● Vabysmo	Wet AMD; Diabetic Macular Edema	0.5%
 	● Ohtuvayre	Chronic Obstructive Pulmonary Disease	3%
	Rylaze	Acute Lymphoblastic Leukemia	Tiered low-single-digit
	● Capvaxive	Pneumococcal Disease	Low-single-digit
 	● Ojemda	R/R Pediatric Low-Grade Glioma	Mid-single-digit
	● Zelsuvmi	Molluscum Contagiosum	13%
	● Miplyffa	Niemann-Pick Type C	Mid-single-digit
	Vaxneuvance	Pneumococcal Disease	Low-single-digit
	Teriparatide	Osteoporosis	25% to 40%*
	Nexterone	Ventricular Fibrillation	Low-single-digit
	Pneumosil	Pneumococcal Disease	Low-single-digit
	● Tzielid	Type-1 Diabetes	Less than 1%
	● Ry Junea	Pediatric Myopia	Low double-digit to high-teens

● New investments/approvals since 2022

* Represents gross profit share, not royalty rate

Key Pipeline Partnered Programs

All key pipeline programs represent new or follow-on investment activity since 2022

Developer(s)	Program	Indication(s)	Phase	Royalty Rate
	QTORIN Rapamycin	Microcystic Lymphatic Malformations Cutaneous Venous Malformations	Reg Phase 3 Ready	8–9.8%
	Lasofoxifene	Metastatic Breast Cancer	Phase 3	6–10%
	AVIM Virtue SAB	Hypertension In-Stent Restenosis	Pivotal	High-teens<\$100M Mid-single-digit >\$100M ²
 		Frontline Pediatric Low-Grade Glioma	Phase 3	Mid-single-digit
	Mezagitamab	IgA Nephropathy Immune Thrombocytopenia	Phase 3	Low-single-digit
	Osavampator ¹	Major Depressive Disorder	Phase 3	Low-to mid-single-digit
	Volixibat	Primary Sclerosing Cholangitis Primary Biliary Cholangitis	Phase 2b	Low-to mid-single-digit
	D-Fi	Dystrophic Epidermolysis Bullosa	Phase 3	Mid-single-digit
	Bot/Bal	Microsatellite-Stable Colorectal Cancer	Phase 3	2.625%
 	OHB-607	Bronchopulmonary Dysplasia Prevention	Phase 2b	Low-to mid-single-digit
Undisclosed	Anti-TL1A	Ulcerative Colitis/Crohn's Disease	Phase 3	Low-single-digit

XOMA High-Priority Pipeline Assets



Mezagitamab

Catalyst: Ph 3 Results Late-'27 to Early-'28

Indication: ITP, IgAN

Royalty Rate: Low-single-digit

Peak Sales¹: \$1.5B+

Peak Royalty: \$30M+



Volixibat

Catalyst: PSC: Potential NDA Submission H1 '27

PBC: Potentially Pivotal Ph 2b Results Q1 '27

Indication: PSC and PBC

Royalty Rate: Low-to-mid-single-digit

Peak Sales²: \$1B+

Peak Royalty: \$45M+



Osavampator

Catalyst: Phase 3 Results H2 '27

Indication: Major Depressive Disorder

Royalty Rate: Low-to mid-single-digit

Peak Sales³: \$500M-1.8B

Peak Royalty: Up to \$80M



Catalyst: Phase 3 Results '27

Indication: Frontline pediatric low-grade glioma

Royalty Rate: Mid-single-digit

Peak Sales⁴: \$500M

Peak Royalty: \$25M

¹ Peak sales estimates provided by our partner in their latest corporate presentation

² Peak sales consensus estimate per FactSet as of the date of this presentation

³ Limited analyst estimates available in FactSet. Range provided based on available information in FactSet as of the date of this presentation

⁴ Peak sales estimate for 1L pLGG indication expansion from Day One investor presentation published on 2/28/2026

2026 Portfolio Activity

2026 Developments

- ✓  **FILSPARI[®]**
(sparsentan) tablets 200 mg/400 mg NDA approval & commercial launch in FSGS
- ✓  **mirum** Volixibat Phase 2b potentially registrational readout in primary sclerosing cholangitis
- ✓  **palvella**
THERAPEUTICS QTORIN rapamycin NDA acceptance in microcystic lymphatic malformations
- ✓  **ojemda[™]** Japan approval
- ✓  **FILSPARI[®]**
(sparsentan) tablets 200 mg/400 mg Regulatory submission in Japan (Chugai)
- ✓  **palvella**
THERAPEUTICS QTORIN rapamycin Phase 2 initiation in clinically significant angiokeratomas
- ✓  **Orchestra**
BioMed Full enrollment target exceeded in the BACKBEAT trial of AVIM Therapy

New Portfolio Additions

- ✓  **XOMA**
ROYALTY Acquisition of XOMA including 3 key commercial assets
- ✓  **AVENCELL** AvenCell Pipeline
- ✓  **Santen**
ryjunea[®] Ryjunea
- ✓  **PERCEPTIVE**
ADVISORS Soticlestat
- ✓  **Immedica**
pharma Ganaxolone IV

 New asset additions from portfolio management

Portfolio Potential Catalysts Through 2027

Pivotal Trial Readouts

Up To 7 Pivotal Trial Readouts Anticipated Through 2027



AVIM



Volixibat



Lasofexifene



Mezagitamab
Osavampator¹



FDA Approval

Potential FDA Approval for
QTORIN Rapamycin in MLM



Geographic Expansion

Potential Geographic Expansion
for Commercial- Stage Products



1. Osavampator is being developed by Takeda in Japan and by a Takeda partner outside Japan



Investment Update

Paul Hadden

LIGAND

2026 YTD Investment Activity

>180
Investments reviewed

~60% to CDA

115
CDAs signed

3% to close

6
Investments closed

Investments reviewed
On track to best prior years

CDAs signed
Highest in the past four years

2026 closed investments

High \$

XOMA

Medium \$

Sydnexis

AvenCell

Small \$

Agenus

Primrose

Zerion

NOTE: Agenus and Primrose represent follow-on investments; Zerion represents a small strategic investment

Ryjunea: \$23M for Europe's First Pediatric Myopia Drug

\$23M 

Upfront payment for Sydnexis' royalty rights under its Santen license

Royalty Tiered low-double-digit to high-teens on net sales

Territory Europe, Middle East and Africa

Milestones Certain milestone payments

Retained Sydnexis keeps the U.S. and other non-Santen territories

WHY IT MATTERS

1st

First and only approved drug to slow pediatric myopia (nearsightedness) progression

EU + UK

Approved by the European Commission and UK MHRA

14M

Patients in Europe affected in 2025, per Santen, which names myopia a key growth area

AvenCell: up to \$47M Royalty on a Next-Gen CAR-T Platform

Up to \$47M



Royalty financing plus a concurrent Series C equity investment

Financing	Up to \$41M royalty financing
Equity	Up to \$6M in AvenCell's Series C
Royalty	Mid-single-digit to low-double-digit on worldwide net sales of all future pipeline assets
Tranches	At closing: \$6M royalty + \$3M equity Three later tranches: tied to clinical milestones and other conditions

PLATFORM

CRISPR-engineered allogeneic CAR-T with a switchable CAR for greater activity control; off-the-shelf, with potential in blood cancers and autoimmune disease


PIPELINE

Ph1

Ph2

Ph3

AVC-201



Phase 1b · Anti-CD123 CAR-T in R/R AML, which has no approved cell therapy

AVC-203



Phase 1a · B-cell malignancies



Q&A

LIGAND